Leaders | Danger ahead

What the Omicron variant means for the world economy

Look to China for the likeliest source of a growth slowdown

A LITTLE MORE than a year after the first success of a covid-19 vaccine in a clinical trial, a sense of dread has struck much of the world. The Omicron variant of the coronavirus, first publicly identified on November 24th, may be able to circumvent the defences built up by vaccination or infection with covid-19. The World Health Organisation declared that Omicron poses a “very high” global risk. The boss of Moderna, a vaccine-maker, warned that existing jabs may struggle against the heavily mutated new variant. Faced with the ghastly prospect of yet more lockdowns, closed borders and nervous consumers, investors have reacted by selling shares in airlines and hotel chains. The price of oil has slumped by roughly $10 a barrel, the kind of drop often associated with a looming recession.

This article appeared in the Leaders section of the print edition under the headline “Danger ahead”

The threats to the world economy

From the December 4th 2021 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

Keir Starmer surrounded by the Eu stars

Sir Keir Starmer should aim higher in his reset with the EU

And he needs to be clearer about what Britain wants

illustration of a world map outlined by a single red electrical cord, with a plug at one end and a socket at the other

To make electricity cheaper and greener, connect the world’s grids

Less than 3% of the world’s power is internationally traded—a huge wasted opportunity


Chinese AI is catching up, posing a dilemma for Donald Trump

The success of cheap Chinese models threatens America’s technological lead


America has an imperial presidency

And in Donald Trump, an imperialist president for the first time in over a century

Tariffs will harm America, not induce a manufacturing rebirth

Donald Trump’s pursuit of tariffs will make the world poorer—and America, too 

How to improve clinical trials

Involving more participants can lead to new medical insights